EMEA-001474-PIP02-16-M02 - paediatric investigation plan

Pembrolizumab

Key facts

• Invented name:
  Keytruda
• Active Substance:
  Pembrolizumab
• Therapeutic area:
  Oncology
• Decision number:
  P/0534/2021
• PIP number:
  EMEA-001474-PIP02-16-M02
• Pharmaceutical form(s):
  • Concentrate for solution for infusion
  • Powder for concentrate for solution for infusion
• Condition(s) / indication(s):
  Treatment of Hodgkin lymphoma
• Route(s) of administration:
  Intravenous use
• Decision type:
  PM: decision on the application for modification of an agreed PIP
• Decision date:
  30/01/2018

Decision

P/0008/2018: EMA decision of 30 January 2018 on the acceptance of a modification of an agreed paediatric investigation plan for pembrolizumab (Keytruda), (EMEA-001474-PIP02-16-M02)

AdoptedReference Number: EMA/28103/2018